122 related articles for article (PubMed ID: 20872622)
1. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials.
Chen YF; Wang SJ; Khin NA; Hung HM; Laughren TP
Pharm Stat; 2010; 9(3):217-29. PubMed ID: 20872622
[TBL] [Abstract][Full Text] [Related]
2. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
3. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
5. An optimal adaptive design to address local regulations in global clinical trials.
Luo X; Shih WJ; Ouyang SP; Delap RJ
Pharm Stat; 2010; 9(3):179-89. PubMed ID: 20872620
[TBL] [Abstract][Full Text] [Related]
6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
7. Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective.
Ando Y; Hamasaki T
Pharm Stat; 2010; 9(3):190-200. PubMed ID: 20737442
[TBL] [Abstract][Full Text] [Related]
8. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
[TBL] [Abstract][Full Text] [Related]
9. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
10. The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.
Gopalakrishnan M; Zhu H; Farchione TR; Mathis M; Mehta M; Uppoor R; Younis I
J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141721
[TBL] [Abstract][Full Text] [Related]
11. Consideration of regional difference in design and analysis of multi-regional trials.
Hung HM; Wang SJ; O'Neill RT
Pharm Stat; 2010; 9(3):173-8. PubMed ID: 20872619
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
[TBL] [Abstract][Full Text] [Related]
13. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
Welge JA; Keck PE
Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial design issues in schizophrenic research.
Casey DE
J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
16. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
18. Placebo response and antidepressant clinical trial outcome.
Khan A; Detke M; Khan SR; Mallinckrodt C
J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM; Smith L
Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
[TBL] [Abstract][Full Text] [Related]
20. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]